Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford

doi:10.3748/wjg.v26.i30.4428

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 26, Issue 30

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8034)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-5) series.

Item

Count

PDF

612

WORD

224

HTML

4340

Figures (1-3)

321

Tables (1-5)

269

Sum=5766

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

801

Download

1467

Sum=2268

Aug 14, 2020 (publication date) through Nov 26, 2024

Times Cited of This Article

Times Cited (17)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Gastroenterol. Aug 14, 2020; 26(30): 4428-4441
Published online Aug 14, 2020. doi: 10.3748/wjg.v26.i30.4428

Table 2 Response and remission at 3 mo of vedolizumab therapy

	Total	Australia	Oxford	P value
Response, n (%)	208 (79)	157 (83)	51 (70)	0.01
Remission, n (%)	148 (56)	104 (55)	44 (59)	0.58
	Total	Anti-TNF naive	Anti-TNF exposed	P value
Response, n (%)	208 (79)	138 (83)	70 (72)	0.03
Remission, n (%)	148 (56)	109 (66)	39 (40)	< 0.001
	Anti-TNF exposed	Primary LOR	Secondary LOR	P value
Response, n (%)	70 (72)	30 (73)	40 (71)	0.85
Remission, n (%)	39 (40)	16 (39)	23 (41)	0.83

VDZ: Vedolizumab; TNF: Tumor necrosis factor; Primary LOR: Primary loss of response to anti-TNF agent; Secondary LOR: Secondary loss of response to anti-TNF agent.

Citation: Pulusu SSR, Srinivasan A, Krishnaprasad K, Cheng D, Begun J, Keung C, Van Langenberg D, Thin L, Mogilevski T, De Cruz P, Radford-Smith G, Flanagan E, Bell S, Kashkooli S, Sparrow M, Ghaly S, Bampton P, Sawyer E, Connor S, Rizvi QUA, Andrews JM, Mahy G, Chivers P, Travis S, Lawrance IC. Vedolizumab for ulcerative colitis: Real world outcomes from a multicenter observational cohort of Australia and Oxford. World J Gastroenterol 2020; 26(30): 4428-4441
URL: https://www.wjgnet.com/1007-9327/full/v26/i30/4428.htm
DOI: https://dx.doi.org/10.3748/wjg.v26.i30.4428